Alpha 2.0
Login Register
» Authors » B Standaert

B Standaert

Explore the profile of B Standaert including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 32
Citations 101
Followers 0
Related Specialties
Public Health
Pharmacology
Biomedical Engineering
Top 10 Co-Authors
P Kadende
L Denis
P Piot
V Nelen
N Nitunga
J Mertens
B Rash
F Niragira
A Martin
A Alwan
Published In
Value Health
Arch Belg
Prog Clin Biol Res
Vaccine
Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study
Standaert B, Dort T, Linden J, Madan A, Bart S, Chu L, et al.
Health Qual Life Outcomes . 2019 May; 17(1):80. PMID: 31060567
Background: This study aims to describe the short-term reactogenicity of the AS03-adjuvanted H5N1 vaccine expressed through adverse events (AEs) and quality-adjusted life-day (QALD) scores. The AEs are likely to be...
2.
Measuring the cost of a pediatric vaccine administration in the UK
Mokiou S, Standaert B, Li X, De Cock E
Vaccine . 2017 Dec; 36(2):237-242. PMID: 29208324
The administration of a vaccine dose involves a series of activities prior to and on the day of vaccine delivery. Total vaccination cost should include the cost of each activity,...
3.
Development of a Survey to Quantify Parents' Priorities for Vaccinating Children Against Rotavirus
Hauber A, Standaert B, Poulos C
Value Health . 2016 May; 17(7):A681. PMID: 27202517
No abstract available.
4.
Allocating Vaccine Funds for Pneumococcal Vaccination of Infants and Older Adults: A Method for Strategic Evaluation in the Netherlands
Delgleize E, Standaert B
Value Health . 2016 May; 17(7):A676. PMID: 27202491
No abstract available.
5.
How Do Decision Makers in Europe Value Other Economic Evaluation Tools Than Cost-Effectiveness Analysis for Vaccines?
Hohne J, Demarteau N, Saka O, Standaert B, Kleintjens J
Value Health . 2016 May; 17(7):A675-6. PMID: 27202482
No abstract available.
6.
Workflow Mapping for Paediatric Vaccination Process in the United Kingdom (Uk): A Precursor of A Time and Motion (T&M) Study
Mokiou S, De C, Standaert B
Value Health . 2016 May; 17(7):A582. PMID: 27201968
No abstract available.
7.
Health Economic Model On the Costs and Effects of Rotavirus Vaccination in Romania
Preda A, Moise M, Standaert B
Value Health . 2016 May; 17(7):A509. PMID: 27201561
No abstract available.
8.
Measuring and Observing Positive And Negative Externalities Caused By Vaccines: Do We Have The Right Assessment Approach Available?
Lefebvre C, Terlinden A, Standaert B
Value Health . 2016 May; 17(7):A450. PMID: 27201234
No abstract available.
9.
Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium
Standaert B, Alwan A, Strens D, Raes M, Postma M
Hum Vaccin Immunother . 2015 Apr; 11(9):2266-73. PMID: 25902371
During each winter period hospital emergency rooms and pediatric wards are often overwhelmed by high patient influx with infectious diseases leading to chaotic conditions with poor quality of care (QoC)...
10.
Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK
Martin A, Batty A, Roberts J, Standaert B
Vaccine . 2009 May; 27(33):4520-8. PMID: 19446594
This study estimated the cost-effectiveness of infant rotavirus vaccination with Rotarix in the UK, taking into account community rotavirus infections that do not present to the healthcare system. A Markov...